Faruqi and Faruqui, LLP Logo
Share this page

In re Aggrenox Antitrust Litig., No. 14-2516 (D. Conn.)

Summary

In the Aggrenox case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Boehringer Ingelheim’s combination stroke prevention drug, Aggrenox.  The case alleges that Boehringer paid its would-be generic competitors (Duramed, later known as Barr, and still later known as Teva) to delay launching their less-expensive generic versions of Aggrenox, in what is known as a “pay for delay” conspiracy. The case settled for $146 million in late 2017.

Contact Counsel

Peter Kohn
Joseph T. Lukens
Faruqi & Faruqi, LLP
1617 JFK Boulevard, Suite 1550
Philadelphia, PA 19103
Tel: (215) 277-5770

Email:

Case Details

Date:

  • 12/02/2013

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.